第一代和第二代布鲁顿的氨酸激酶抑制剂之间的一年不良事件的比较:一项回顾性研究
Ao Ito1, Kaori Ito1,2, Chisako Iriyama2
1Faculty of Pharmacy, Meijo University, Nagoya, JPN.
Cureus
|November 3, 2025
概括
这项研究比较了布鲁顿的氨酸激酶抑制剂 (BTKi) 在现实实践中的不良事件. 所有的BTKi都导致骨髓抑制,感染和出血,心脏事件只见于ibrutinib.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿的氨酸激酶抑制剂 (BTKi) 对于治疗血液性恶性瘤至关重要.
- 与第一代药物相比,第二代BTKi的目标是减少非目标效应.
- 对BTKi的不良事件 (AEs) 的真实世界比较数据有限.
研究的目的:
- 调查与三种BTKi相关的特定不良事件 (AEs) 的频率和严重程度:易布鲁替尼 (IBR),提拉布鲁替尼 (TIR) 和阿卡拉布鲁替尼 (ACB).
- 在IBR,TIR和ACB中比较特别感兴趣的现实世界AE,包括骨髓抑制,感染,出血和心脏事件.
主要方法:
- 在2016年3月至2025年3月期间接受BTKi (IBR,TIR,ACB) 的患者的回顾性分析.
- 从电子医疗记录收集数据,重点关注细胞衰减,感染,出血和心血管AE多达一年.
- 使用常用术语标准对不良事件的AE评级版本5.0.0.
主要成果:
- 在ibrutinib组 (n=24),观察到细胞衰减 (87.5%),感染 (37.5%),出血 (33.3%) 和心血管副作用 (16.6%).
- 在 Tirabrutinib 组 (n=24),发生了细胞衰减 (70.8%),感染 (29.1%) 和出血 (25.0%).
- 在acalabrutinib组 (n=5) 中,在80.0%的患者中观察到细胞衰减.
结论:
- 所有评估的BTKi药物都与骨髓抑制,感染和出血有关.
- 与心脏相关的副作用特别在ibrutinib的治疗中被发现.
- 发生3级或更高的事件需要在BTKi治疗期间对患者进行仔细监测.
相关概念视频
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
395
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
395
01:16Therapeutic Drug Monitoring: Overview and Classification
293
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
293
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
01:29Therapeutic Drug Monitoring: Affecting Factors
193
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
193
01:20Comparing the Survival Analysis of Two or More Groups
548
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
548
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
145
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
145